←
FierceBiotech29,789 posts
FierceBiotech avatar

FierceBiotech

@FierceBiotech

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

◷ Joined December 2008▧ 170 Photos and videos
FierceBiotech avatar
FierceBiotech@FierceBiotech·22h

Marrow Therapeutics has launched with $173 million in funding to advance a preclinical therapy targeting sickle cell disease and beta thalassemia. fiercebiotech.com/biotech/ma…

FierceBiotech avatar
FierceBiotech@FierceBiotech·22h

Isomorphic Labs has pulled off another massive financing, raising $5 billion in a series C just six months after securing $2.1 billion for its AI drug development platform. fiercebiotech.com/biotech/is…

FierceBiotech avatar
FierceBiotech@FierceBiotech·22h

Another setback for Kyntra Bio. The former FibroGen has scrapped its phase 2 prostate cancer ADC program after failing to meet an efficacy threshold. fiercebiotech.com/biotech/ky…

FierceBiotech avatar
FierceBiotech@FierceBiotech·22h

Could 2027 be Europe's year to shine? At Fierce's London Life Sciences Week event, investors weighed the region's biotech funding challenges and opportunities. fiercebiotech.com/biotech/fi…

FierceBiotech avatar
FierceBiotech@FierceBiotech·Nov 13

Sanofi-backed Windward Bio has hit its $225M IPO target to advance its respiratory pipeline, even as fellow biotech Rezera delays its own public offering, citing market conditions. fiercebiotech.com/biotech/sa…

FierceBiotech avatar
FierceBiotech@FierceBiotech·Nov 5

Rezera, formerly known as NodThera, is targeting $181 million in IPO proceeds to advance its lead NLRP3 inhibitor into a phase 3 trial for peripheral artery disease next year. fiercebiotech.com/biotech/re…

FierceBiotech avatar
FierceBiotech@FierceBiotech·Nov 4

Ultragenyx is cutting 20% of its workforce and shelving drug development programs as it looks to halve R&D spending and reach profitability in 2027. The overhaul follows a string of clinical setbacks. fiercebiotech.com/biotech/ul…

FierceBiotech avatar
FierceBiotech@FierceBiotech·Nov 4

After $2.2 billion in impairment charges weighed on quarterly profits, Novo Nordisk is still looking to acquisitions to fill gaps in its pipeline. fiercebiotech.com/biotech/no… $NVO

FiercePharma avatar
⟳ FierceBiotech retweeted
FiercePharma@FiercePharma·Oct 28

Enhertu has transformed HER2 breast cancer treatment and set a high bar for the next generation of drugs. Now, the race is on to develop something even better, but finding a worthy successor is proving to be easier said than done. fiercebiotech.com/biotech/ad…